Collaborators

NEOPEC is a collaboration of Victorian-based organisations brought together with funding from  a Victorian Government science and innovation grant to further the development of intellectual property developed at the O'Brien Institute.

 

The O'Brien Institute (OBI) is a world-leading tissue engineering research and training organisation, and has developed the initial IP for the vascularised chamber. It is leading preclinical studies and the human clinical trial and is working with St. Vincent's Hospital on clinical development. OBI will also head up the training of surgeons, both locally and internationally, in the Neopec procedure.
St. Vincent's Hospital St. Vincent’s Hospital Melbourne Ltd is making available its excellent preclinical and surgical facilities, and clinical study management and is providing additional administrative support to NEOPEC.
The University of Melbourne Department of Chemical and Biomolecular Engineering (UM) is researching and developing approved and novel biodegradable materials with different physicochemical properties, and the facilities and expertise to match the shape, strength and degradation rate of devices to the biological need.
The Particulate Fluids Processing Centre

Anatomics is an Australian based medical device company manufacturing and marketing patient specific surgical products from CT scan data to reconstructive surgeons both locally and internationally. Anatomics has developed a suite of software products to improve efficiency in ordering and production of products in the surgical setting including web integrated ordering portals, 3D processing software and database and logistic tools. Anatomics has extensive experience manufacturing medical devices from a range of materials including titanium, acrylates, silicone and other polymers. Anatomics operates under a Quality Management System equivalent to ISO13485.

 
Cogentum is a boutique innovation and growth consulting firm based in Melbourne Australia. Cogentum's role in the Neopec project is to assist with the commercial aspects of bringing this innovative medical technology to market, including business planning, strategic marketing and communication planning, marketing research and business development.  Its particular focus is on helping Neopec better understand and respond to the needs of women who require breast reconstruction and the medical communities who provide care and support throughout their cancer treatment and recovery. Cogentum brings a market oriented and evidence based approach to helping Neopec make confident decisions about the future. Its work will help to mitigate the risk of market failure and more importantly to optimise the commercial success of the innovation.